point being, with less than a 100-200k volume days, it wont take much for the operators to bring it back down. just saying, don't go getting giddy people, this story still has many chapters. resist the urge to jump to the end of the book.
I think w 130m out there are plenty of shares to choose from. Our holdings locked up wont do anything to prevent them from shorting, albeit at their eventual peril God willing.
They wont be moving to a different exchange anytime soon, ie NYSE, NASDAQ. They will however move from OTC PINK to OTCQB upon being compliant w SEC reporting.
This is one of the things I don't understand. Except for IVF Phoenix the other two new clinics don't have any info on their websites.
You would think that at the very least CARE / Dr Doody would have had everything ready to go upon going live with the Press Release.
They have a website domain that still hasn't gone live. Makes zero sense to me. Whoever is doing their mktg should be fired or maybe that's the problem, they don't have anyone but its just common sense to have things ready to go.
The clinic in Wash DC announced today basically the same thing, no info on today's press release.
Makes zero sense to me!
I was reading an interesting article on the diff between OTCBB and OTCQB, long story short if this is correct the switch will be automatic once they have met SEC reqs...
Once current again with the SEC, the Issuer will be moved immediately back to the OTCQB marketplace.
the longer this gem stays under the radar, the more that can be purchased at these ridiculous levels. of course, you need a long term horizon here.
read the investor updates on the website. The company has provided what they can and given information on next steps but there are no details as of yet.
I wouldn't go that far. Many of those in trials have partners with deep pockets that are financing those trials or marketing and sales efforts. You are also talking about drug candidates with perhaps billion dollar markets
IVOB is still an OTC Pink and trading for pennies. Granted, roughly 30-40 pennies but pennies nonetheless. It is not without risk, but those that know what they have here, I believe, will be rewarded in the future.
found this post that Joe had previously made....sounds right on target.
Trading strategy from the 1930s that hedge funders don’t want you to know about.
It takes a while for a hedge pro to accumulate a position in advance of a big move as buying too many shares at once would cause the price to rise too quickly. The preparation of an important move in the market takes a considerable time. A large operator or investor acting singly cannot often, in a single day’s session, buy 25,000 to 100,000 shares of stock without putting the price up too much. Instead, he takes days, weeks or months in which to accumulate his line in one or many stocks.
Instead, here’s how he sets it up: first, he’ll “shake out” the little guys by forcing the stock lower in order to get a better price. He prefers to do this while the market is weak, dull, inactive and depressed. To the extent that they are able, he, and the other interests with whom he works, bring about the very conditions which are most favorable for accumulation of stocks at low prices. When he wishes to accumulate a line, he raids the market for that stock, makes it look very weak, and gives it the appearance of heavy liquidation by sending in selling orders through a great number of brokers. Then, he will try to time the top of his planned price rise with some “good news” about the stock he may already know about. You have often noticed that a stock will sell at the highest price for many months on the very day when a stock dividend, or some very bullish news, appears in print. This is not mere accident. The whole move is manufactured. Its purpose is to make money for inside interests — those who are operating in the stock in a large way. And this can only be done by fooling the public, or by inducing the public to fool themselve
sg, maybe I was a lil hasty with that comment. It obviously is a very important issue and as they revealed the SEC requested a lot of documentation. Again I wont be surprised if it takes longer than they estimated but perhaps you are correct in that they padded the estimated time. Hopefully we'll find out soon.
This is a huge opportunity that they can hit out of the park. There is much activity and talk about increasing insurance coverage for IVF. Having an option at half the cost w/ equivalent success rates makes it much more palatable for insurance companies.
I have to disagree with the late May to report financials. They said June which to me means end of June at best and wouldn't be surprised if it goes beyond that. The materials the SEC requested were not on the light side and again, the past doesn't really matter here. I would understand those efforts taking a back seat to other more important tasks such as developing clinic partnerships, etc.
I'm not sure if you realize what this product is all about. Of course many couples can choose to go with IVF which is much more expensive. The whole point of this product is to bring "affordable" IVF to the masses for those millions of couples who CANNOT afford $12,000 or more per treatment with a product that has already shown equivalent rates to traditional IVF. It just took the FDA forever and a day to come around to that conclusion and finally give them clearance.
The most recent Invaron / CARE trial is not the only trial that has been performed. Prior to this INVO submitted various results to the FDA ...
Even though we have more than proven the efficacy and safety of the INVOcell with its ability to assist couples in having a child, every country needs to “prove” it for themselves within their own population. It is one of the hurdles and steps we must go through to gain acceptance in each market. On a very positive note, as we continue to expand we believe we have helped over 500 couples in having babies during the past few years.
450 procedures done in Colombia, Peru, Bolivia and Brazil.
The combined results of the submitted procedures for woman across all age groups from their 20s to there 40s are: 148 clinical pregnancies equaling a 33% efficacy rate, 21 (14%) multiple births and 127 healthy babies born to date.
Dr. Elkin Lucena of CECOLFES in Columbia presented the data from a 172 cycle mild stimulation protocol INVO clinical study with ICSI (Intra Cytoplasmic Sperm Injection) for severe male factor. He obtained a 40% clinical pregnancy rate, his poster presentation is on our website. The INVOcell and Intra-Vaginal Culture process was extremely well received by the Assisted Reproduction Community and by ASRM who has endorsed the INVOcell as a lower cost alternative to IVF